BioCryst Pharma (NASDAQ: BCRX) reported Q2 EPS of $0.15, $0.14 better than the analyst estimate of $0.01. Revenue for the quarter came in at $163.35 million versus the consensus estimate of $149.82 million.

GUIDANCE:

BioCryst Pharma sees FY2025 revenue of $580-600 million, versus the consensus of $608.4 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.